Arcturus Therapeutics Holdings Inc. (ARCT), a commercial mRNA medicines company with a pipeline of multiple therapeutic candidates in advanced clinical trial development, is scheduled to report interim data from its cystic fibrosis study of ARCT-032 this month.
ARCT-032 is an inhaled investigational mRNA therapeutic designed to express a normal functional cystic fibrosis transmembrane conductance regulator (CFTR) gene in the lungs of individuals with cystic fibrosis. Mutations in the CFTR gene cause cystic fibrosis. There are over 2,000 mutations of the Cystic Fibrosis Transmembrane (CFTR) gene.
For comments and feedback contact: editorial@rttnews.com
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.